Details
Stereochemistry | MIXED |
Molecular Formula | C21H45N3 |
Molecular Weight | 339.6021 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCC(CC)CN1CN(CC(CC)CCCC)CC(C)(N)C1
InChI
InChIKey=DTOUUUZOYKYHEP-UHFFFAOYSA-N
InChI=1S/C21H45N3/c1-6-10-12-19(8-3)14-23-16-21(5,22)17-24(18-23)15-20(9-4)13-11-7-2/h19-20H,6-18,22H2,1-5H3
Molecular Formula | C21H45N3 |
Molecular Weight | 339.6021 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/11917691
Curator's Comment: description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/11917691
Hexetidine is very safe oral antiseptic with broad antibacterial and antifungal activity in vivo and in vitro. It has local-anesthetics, astringent and deodorant activity. Also, it has very strong antiplac effects. Resistention of microorganisms on hexetidine is short and transient. These characteristics give important therapeutic role in treatment of oral infections. In the UK, hexetidine is the active ingredient in the medicated mouthwash branded Oraldene. Oraldene contains 0.1 g/100 ml of hexetidine. In Germany, hexetidine is used for vaginal antisepsis.
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
0.1 % 1 times / day multiple, oromucosal Dose: 0.1 %, 1 times / day Route: oromucosal Route: multiple Dose: 0.1 %, 1 times / day Sources: |
unhealthy, 38.2 years (range: 18–61 years) n = 46 Health Status: unhealthy Condition: supragingival plaque | gingivitis Age Group: 38.2 years (range: 18–61 years) Sex: M+F Population Size: 46 Sources: |
|
10 mg 1 times / day multiple, vaginal Dose: 10 mg, 1 times / day Route: vaginal Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 100 |
PubMed
Title | Date | PubMed |
---|---|---|
[Analytical profile of purified hexetidine (author's transl)]. | 1975 |
|
[Disturbances of taste from oral disinfectants (author's transl)]. | 1978 Oct |
|
The erosive effects of some mouthrinses on enamel. A study in situ. | 2001 Apr |
|
The concomitant development of poly(vinyl chloride)-related biofilm and antimicrobial resistance in relation to ventilator-associated pneumonia. | 2001 Oct |
|
A comparative study in vivo of the therapeutic effect of triclosan, hexetidine and chitosan. | 2002 |
|
[Hexetidine--an oral antiseptic]. | 2002 |
|
Nonaqueous capillary electrophoretic analysis of hexetidine in a commercial liquid formulation. | 2002 Apr |
|
Physicochemical characterization of hexetidine-impregnated endotracheal tube poly(vinyl chloride) and resistance to adherence of respiratory bacterial pathogens. | 2002 Jun |
|
An in vitro oral biofilm model for comparing the efficacy of antimicrobial mouthrinses. | 2002 Mar-Apr |
|
Antimicrobial action of Nitens mouthwash (cetyltrimethylammonium naproxenate) on multiple isolates of pharyngeal microbes: a controlled study against chlorhexidine, benzydamine, hexetidine, amoxicillin, amoxicillin-clavulanate, clarithromycin, and cefaclor. | 2002 Sep |
|
Antiplaque and antigingivitis effectiveness of a hexetidine mouthwash. | 2003 Jul |
|
Clinical study on the effectiveness and side effects of hexetidine and chlorhexidine mouthrinses versus a negative control. | 2005 Sep |
|
Fluconazole and/or hexetidine for management of oral candidiasis associated with denture-induced stomatitis. | 2005 Sep |
|
[Stopangin in the treatment of pharyngeal inflammation]. | 2006 |
|
Fluconazole and/or hexetidine for management of oral candidiasis associated with denture-induced stomatitis. | 2006 Jul |
|
Mucocutaneous lesions of Behcet's disease. | 2007 Aug 31 |
|
[Efficacy of an antiseptic dialysis of purulent wounds in the dentofacial region with hyvalix]. | 2007 Jul-Sep |
|
[Combined local therapy in oropharyngeal diseases]. | 2008 |
|
Efficacy of vaginal misoprostol before hysteroscopy for cervical priming in patients who have undergone cesarean section and no vaginal deliveries. | 2008 Jul-Aug |
|
Identification by automated screening of a small molecule that selectively eliminates neural stem cells derived from hESCs but not dopamine neurons. | 2009 Sep 23 |
|
Parotid gland swelling following mouthrinse use. | 2010 Nov |
|
The plaque inhibitory effect of a CPC mouthrinse in a 3-day plaque accumulation model - a cross-over study. | 2010 Nov |
|
The effect of hexetidine mouthwash on the prevention of plaque and gingival inflammation: a systematic review. | 2011 Aug |
Patents
Sample Use Guides
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/6583906
Curator's Comment: all information about in vitro activity in german
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:19:20 GMT 2023
by
admin
on
Sat Dec 16 17:19:20 GMT 2023
|
Record UNII |
852A84Y8LS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28394
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
||
|
WHO-ATC |
A01AB12
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
||
|
WHO-ATC |
G01AX16
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
||
|
WHO-VATC |
QA01AB12
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
m6009
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000092531
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
D006590
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
C77049
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
5301
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | RxNorm | ||
|
205-513-5
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
141-94-6
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
Hexetidine
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
852A84Y8LS
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
3607
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
3277
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
DTXSID1045297
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
DB08958
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
522
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
7828
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
SUB08037MIG
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
17764
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL144673
Created by
admin on Sat Dec 16 17:19:20 GMT 2023 , Edited by admin on Sat Dec 16 17:19:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |